Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Skin & dermatology research

Glow Protocol (GLOW): Research Overview

Vendor blend of three peptides sold for skin research. The blend itself has not been trialled.

Also known as GLOW · BPC-157 / TB-500 / GHK-Cu blend

Research use onlyStrongest evidence: controlled clinical trialReviewed
DatabaseReferences

What is Glow Protocol?

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

What is Glow Protocol researched for?

  • Theoretical synergistic effects; formal combination studies are limited
  • BPC-157 and TB-500 components support tissue regeneration
  • GHK-Cu stimulates collagen production

How does Glow Protocol work?

BPC-157 provides anti-inflammatory effects; TB-500 supports angiogenesis; GHK-Cu stimulates collagen production. Fixed-ratio combinations may deliver individual peptides outside optimal therapeutic ranges.

References

  1. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth

    Staresinic M, Sebecic B, Patrlj L, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003

    BPC-157 improved Achilles tendon recovery biomechanically, functionally, and microscopically; reversed HNE-mediated growth inhibition of tendocytes.

    Animal study · PMID 14554208

  2. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A · International journal of molecular sciences · 2018

    GHK-Cu modulates over 4,000 human genes, stimulates collagen, elastin, and GAG synthesis, and promotes tissue repair across skin, lung, bone, liver, and stomach.

    PMID 29986520

  3. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

    Wang X, Liu L, Qi L, et al. · Journal of cellular and molecular medicine · 2021

    Phase I trial in 54 healthy subjects demonstrated recombinant thymosin β4 was well tolerated and safe across ascending IV doses up to 25 μg/kg with no significant accumulation.

    Controlled clinical trial · PMID 34346165

  4. No Published Studies on GLOW Combination N/A

    2024

    No clinical or preclinical studies examine the three-peptide GLOW combination; all evidence is extrapolated from individual component research.